Neurological Diseases or ConditionsHealthy Participants
Investigational drug(s) / intervention(s)
medication swallowing
medication swallowing: Three swallow trials will be conducted in randomized order for each of the following conditions:
1. Placebo medication with methylene-blue-dyed water.
2. Placebo medication with a semi-solid vehicle.
3. Placebo medication with the swallowing gel GLOUP®.
Study summary
This research project examines the prevalence of medication-related dysphagia in patients with dysphagia-associated diseases. Its primary aim is to assess how frequently swallowing difficulties occur during medication intake and to evaluate the impact of different consistencies-such as semi-solid formulations and commercial swallowing gels-on the swallowing process. Flexible endoscopic evaluation of swallowing serves as the diagnostic gold standard to determine whether alternative administration forms can facilitate safer swallowing. The findings are intended to support the optimization of medication intake and the prevention of complications in patients with dysphagia.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
Patients:
Adults with a dysphagia-associated disease (neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular disorders; in other centers also ENT-related diseases), for whom FEES is clinically indicated.
Capable of providing informed consent and cognitively able to follow the study protocol.
Healthy Controls Adults without any dysphagia-associated disease (no neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular disorders; no ENT-related diseases with structural abnormalities of the oropharynx or esophagus).
Capable of providing informed consent and cognitively able to follow the study protocol.
Exclusion Criteria:
No additional exclusion criteria beyond those specified in the inclusion criteria.
Primary outcome measure(s)
Medication dysphagia score according to Labeit et al 2022; DOI: 10.1038/s41531-022-00421-9 — on the day of enrollment. This is not a longitudinal study but a one-time examination; all assessments take place on the day of enrollment.
Medication dysphagia swallowing score according to FEES (Labeit et al 2022; doi: 10.1038/s41531-022-00421-9) — on the day of enrollment. This is not a longitudinal study but a one-time examination; all assessments take place on the day of enrollment. as published here: Labeit et al 2022; doi: 10.1038/s41531-022-00421-9
Trial sites (3)
Facility
City
Region
Status
University Hospital Düsseldorf
Düsseldorf
North Rhine-Westphalia
Recruiting
University Hospital Münster
Münster
North Rhine-Westphalia
Recruiting
Hospital Osnabrücl
Onsabrück
Germany
Recruiting
More Heinrich-Heine University, Duesseldorf trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.